Model outputs included costs and QALYs. These were used to calculate the cost-effectiveness of BMS versus conventional treatment, represented as incremental cost-effectiveness ratios (ICER; the difference in cost between two interventions, divided by the difference in their effect [QALYs]). The net monetary benefit (NMB; calculated as the benefit [QALYs] of an intervention multiplied by a willingness-to-pay [WTP] threshold, minus the cost of the intervention) was used as a measure of the value of each treatment in monetary terms. The WTP threshold, corresponding to the maximum cost per health outcome (QALYs) that a health system is willing to pay, was set at £25,000/QALY as per the NICE reference case.[21]

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.